The latest report documenting the troubling state of biotech capital markets (see page A3) served to renew our simmering discontent with other industry pundits and some corporate types who suggest that the biotech lobby's preoccupation with price controls is overblown.

We're also unhappy with related arguments that the preponderance of the Clinton plan is benign for biotech, which should be proving itself through product development instead of playing in the political sandbox.

Hogwash. Here are a couple of reasons why.

The Clinton approach provides another reason for NOT investing in biotech.